First-in-class targets in validated pathways and the right patient subset
Our approach to oncology drug development combines deep understanding of target biology and antibody mechanism of action with rigorous patient selection. This allows us to precisely target likely responders and – enabled by extensive patient biomarker data analysis in the clinic – develop rational combination therapies based on the specific immunomodulatory mechanisms of our drug candidates.
MSC-1 is a clinical stage first-in-class antibody that targets leukemia inhibitory factor (LIF), a pleiotropic cytokine that is overexpressed in most solid tumor types. LIF is hypothesized to drive a broad program of immunosuppression in the tumor microenvironment and supports self-renewal in tumor-initiating cells.
The open-label, Phase I trial is testing MSC-1 as monotherapy in patients with relapsed or refractory metastatic solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of MSC-1, determine the recommended dose for MSC-1 monotherapy and assess the product’s preliminary activity as measured by objective response rate. Secondary objectives include assessing progression-free survival and studying MSC-1’s pharmacokinetics. The clinical trial is conducted in multiple study sites in Europe and North America.